United States Anti-Obesity Prescription Drugs Market Report 2017

Publisher Name :
Date: 08-Dec-2017
No. of pages: 97
Inquire Before Buying

In this report, the United States Anti-Obesity Prescription Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of Anti-Obesity Prescription Drugs in these regions, from 2012 to 2022 (forecast).

United States Anti-Obesity Prescription Drugs market competition by top manufacturers/players, with Anti-Obesity Prescription Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- VIVUS

- Orexigen Therapeutics

- Novo Nordisk

- F Hoffmann La Roche

- Arena Pharmaceuticals

- ...

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

- Bupropion and Naltrexone

- Orlistat

- Lorcaserin

- Phentermine and Topiramate

- Liraglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

- Hospitals Pharmacies

- Retail Pharmacies

- E-commerce

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Anti-Obesity Prescription Drugs Market Report 2017

Table of Contents
United States Anti-Obesity Prescription Drugs Market Report 2017
1 Anti-Obesity Prescription Drugs Overview
1.1 Product Overview and Scope of Anti-Obesity Prescription Drugs
1.2 Classification of Anti-Obesity Prescription Drugs by Product Category
1.2.1 United States Anti-Obesity Prescription Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Anti-Obesity Prescription Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Bupropion and Naltrexone
1.2.4 Orlistat
1.2.5 Lorcaserin
1.2.6 Phentermine and Topiramate
1.2.7 Liraglutide
1.3 United States Anti-Obesity Prescription Drugs Market by Application/End Users
1.3.1 United States Anti-Obesity Prescription Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 E-commerce
1.4 United States Anti-Obesity Prescription Drugs Market by Region
1.4.1 United States Anti-Obesity Prescription Drugs Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.4.3 Southwest Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.4.5 New England Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.4.6 The South Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.4.7 The Midwest Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Anti-Obesity Prescription Drugs (2012-2022)
1.5.1 United States Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2022)
1.5.2 United States Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2022)
2 United States Anti-Obesity Prescription Drugs Market Competition by Players/Suppliers
2.1 United States Anti-Obesity Prescription Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Anti-Obesity Prescription Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Anti-Obesity Prescription Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Anti-Obesity Prescription Drugs Market Competitive Situation and Trends
2.4.1 United States Anti-Obesity Prescription Drugs Market Concentration Rate
2.4.2 United States Anti-Obesity Prescription Drugs Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Anti-Obesity Prescription Drugs Manufacturing Base Distribution, Sales Area, Product Type
3 United States Anti-Obesity Prescription Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Anti-Obesity Prescription Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Anti-Obesity Prescription Drugs Price by Region (2012-2017)
4 United States Anti-Obesity Prescription Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Anti-Obesity Prescription Drugs Price by Type (2012-2017)
4.4 United States Anti-Obesity Prescription Drugs Sales Growth Rate by Type (2012-2017)
5 United States Anti-Obesity Prescription Drugs Sales (Volume) by Application (2012-2017)
5.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Anti-Obesity Prescription Drugs Players/Suppliers Profiles and Sales Data
6.1 VIVUS
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 VIVUS Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Orexigen Therapeutics
6.2.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Novo Nordisk
6.3.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Novo Nordisk Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 F Hoffmann La Roche
6.4.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Arena Pharmaceuticals
6.5.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
7 Anti-Obesity Prescription Drugs Manufacturing Cost Analysis
7.1 Anti-Obesity Prescription Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Anti-Obesity Prescription Drugs
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Anti-Obesity Prescription Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Anti-Obesity Prescription Drugs Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Anti-Obesity Prescription Drugs Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Anti-Obesity Prescription Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Anti-Obesity Prescription Drugs
Figure United States Anti-Obesity Prescription Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Bupropion and Naltrexone Product Picture
Figure Orlistat Product Picture
Figure Lorcaserin Product Picture
Figure Phentermine and Topiramate Product Picture
Figure Liraglutide Product Picture
Figure United States Anti-Obesity Prescription Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Anti-Obesity Prescription Drugs by Application in 2016
Figure Hospitals Pharmacies Examples
Table Key Downstream Customer in Hospitals Pharmacies
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure E-commerce Examples
Table Key Downstream Customer in E-commerce
Figure United States Anti-Obesity Prescription Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers
Figure 2017 United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers
Figure United States Anti-Obesity Prescription Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers
Table United States Market Anti-Obesity Prescription Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Anti-Obesity Prescription Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Anti-Obesity Prescription Drugs Market Share of Top 3 Players/Suppliers
Figure United States Anti-Obesity Prescription Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Anti-Obesity Prescription Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Anti-Obesity Prescription Drugs Product Category
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Region in 2016
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Revenue Market Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Revenue Market Share by Region in 2016
Table United States Anti-Obesity Prescription Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Type (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Share by Type (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Type in 2016
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Type (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Type in 2016
Table United States Anti-Obesity Prescription Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Growth Rate by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Application (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Application in 2016
Table United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
Table VIVUS Basic Information List
Table VIVUS Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Orexigen Therapeutics Basic Information List
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table F Hoffmann La Roche Basic Information List
Table F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Arena Pharmaceuticals Basic Information List
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Anti-Obesity Prescription Drugs
Figure Manufacturing Process Analysis of Anti-Obesity Prescription Drugs
Figure Anti-Obesity Prescription Drugs Industrial Chain Analysis
Table Raw Materials Sources of Anti-Obesity Prescription Drugs Major Players/Suppliers in 2016
Table Major Buyers of Anti-Obesity Prescription Drugs
Table Distributors/Traders List
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Levonorgestrel Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 130
    Levonorgestrel is a hormonal medication which is used in a number of birth control methods. In pill form, sold under the brand name Plan B among others, it is useful within 120 hours as emergency birth control. It becomes less effective the longer after sex and only works before pregnancy has occurred. It is also combined with an estrogen to make Mixture Products. Within an intrauterine device (IUD), sold as Mirena among others, it is effective for long-term prevention of pregnancy. An implantab......
  • Global Equine Pharmaceuticals and Supplements Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 158
    Equine Pharmaceuticals and Supplements are medicines or supplements that are specially used to supplement nutrition and cure diseases. In the last several years, global market of Equine Pharmaceuticals and Supplements developed rapidly, with an average growth rate of 4.52% during 2013 to 2017. In 2017, global revenue of Equine Pharmaceuticals and Supplements is nearly 977 M USD; the actual production is about 13700 K Unit. Market competition is not intense. Boehringer Ingelheim, Me......
  • Global Cabazitaxel Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 132
    Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy. Global cabazitaxel production regions are mainly distributed in USA and Europe. There is no doubt that USA is the largest production region in the world. In......
  • Global Rydapt Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 139
    Rydapt is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. North America is the largest Sales place, with a Sales market share nearly 75.2% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 24.8%. In USA, The National Cancer Institute estimates that in 2017 approximately 21,380 people will be diagn......
  • Global Hyperimmune Globulins Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 159
    Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccine......
  • Global Transforming Growth Factor Beta 1 Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 139
    Transforming growth factor beta 1 or TGF-ß1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, and apoptosis. In humans, TGF-ß1 is encoded by the TGFB1 gene North America is the largest consumption place, with a consumption market share nearly 61.5% in 2017. Following North America, Asia-Pacific and Europe is ......
  • Global Traveler's Diarrhea Therapeutics Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 139
    Traveler's diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. It may be accompanied by abdominal cramps, nausea, fever, and bloating. Occasionally bloody diarrhea may occur. Most travelers recover within four days with little or no treatment. About 10% of people may have symptoms for a week. Traveler's diarrhea is the leading cause of illness among international tra......
  • Global Anticoagulant Drugs Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 130
    Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. According to this study, over the next five years the Anticoagulant Drugs market will register a 5.0% CAGR in terms of revenue, the global market size will reach US$ 31300 million by 2024, from US$ 24600 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Anticoag......
  • Global OTC Herbal and Traditional Medicines Market Growth 2019-2024
    Published: 23-Jan-2019        Price: US 3660 Onwards        Pages: 184
    Herbal medicine--also called botanical medicine or phytomedicine refers to using a plant's seeds, berries, roots, leaves, bark, or flowers for medicinal purposes. Herbalism has a long tradition of use outside of conventional medicine. It is becoming more mainstream as improvements in analysis and quality control along with advances in clinical research show the value of herbal medicine in the treating and preventing disease. Herbal medicine industry is dispersive relatively. Currently, th......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs